Azacitidine (Onureg)
نویسندگان
چکیده
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well patient clinician perspectives, a drug or class. The inform non-binding recommendations that help guide decisions Canada's federal, provincial, territorial governments, with exception Quebec. This review assesses azacitidine (Onureg), tablet 300 mg, oral. Indication: Maintenance therapy in adult patients acute myeloid leukemia who achieved complete remission incomplete blood count recovery following induction without consolidation treatment, not eligible for hematopoietic stem cell transplantation.
منابع مشابه
Injection-Site Reaction Following 5-Azacitidine Injection
Vol. 26 No. 5, 2014 669 Received July 23, 2013, Revised October 22, 2013, Accepted for publication November 1, 2013 Corresponding author: Dong Soo Yu, Department of Dermatology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 271 Cheonbo-ro, Uijeongbu 480-717, Korea. Tel: 82-31-820-3509, Fax: 82-31-846-4799, E-mail: [email protected] This is an Open Acce...
متن کاملAzacitidine in outpatient treatment – single center experience
AIM OF THE STUDY Azacitidine is a hypomethylating agent which is used in the treatment of myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia. Because of good tolerance to the drug, azacitidine can be administered both during hospitalization and in an outpatient setting. The aim of our retrospective analysis was to assess the efficacy of azacitidine treatment i...
متن کاملStability of azacitidine in sterile water for injection.
BACKGROUND The product monograph for azacitidine states that once reconstituted, the drug may be held for only 30 min at room temperature or 8 h at 4°C. Standard doses result in wastage of a portion of each vial, and the cost of this wastage is significant, adding about $156 000 to annual drug expenditures at the authors' institution. OBJECTIVE To evaluate the stability of azacitidine after r...
متن کاملAdvances in myelodysplastic syndrome: nursing implications of azacitidine.
Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, leading to bone marrow failure and peripheral blood cytopenias. MDS is difficult to diagnose because of the absence of symptoms in the early stage of the disease; it often is discovered accidentally during routine physical examinations or blood tests. The U.S. Food a...
متن کاملApproval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
PURPOSE This article summarizes data submitted to the U.S. Food and Drug Administration for marketing approval of azacitidine as injectable suspension (Vidaza, Pharmion Corporation, Boulder, CO) for treatment of patients with myelodysplastic syndrome. EXPERIMENTAL DESIGN In one phase 3 controlled trial, 191 study subjects were randomized to treatment with azacitidine or to observation; an add...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian journal of health technologies
سال: 2022
ISSN: ['2563-6596']
DOI: https://doi.org/10.51731/cjht.2022.237